Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Winer, Eric S. [1 ]
Garcia, Jacqueline S. [2 ]
Stone, Richard M. [1 ]
Wadleigh, Martha [1 ]
Luskin, Marlise R. [1 ]
Stahl, Maximilian [3 ]
Chen, Evan C. [1 ]
Leonard, Rebecca [2 ]
Noyes, Alexis [1 ]
Galinsky, Ilene [2 ]
Deshpande, Rashmi [4 ]
Borderies, Pascal [4 ]
O'Neill, Vincent [4 ]
DeAngelo, Daniel J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Dana Farber Inst, Boston, MA USA
[4] BioXcel Therapeut, New Haven, CT USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186598
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [2] Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Mims, Alice S.
    Solh, Melhem
    Borate, Uma
    Pemmaraju, Naveen
    Borthakur, Gautam
    Roboz, Gail J.
    Powell, Ben
    Severson, Paul
    Matusow, Bernice
    Halladay, Jason
    Hsu, Ching
    Watkins, Paul
    Zhang, Chao
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    DeZern, Amy E.
    BLOOD, 2020, 136
  • [3] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [4] A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Montesinos, Pau
    Al-Ali, Haifa
    Alonso-Dominguez, Juan M.
    Jentzsch, Madlen
    Jongen-Lavrencic, Mojca
    Martelli, Maria Paola
    Rollig, Christoph
    Sica, Simona
    Iadevaia, Riham
    Yablonski, Kaitlin
    Wang, Tianli
    Mahmood, Zafar
    Koenen, Giedre
    Schmidt, Hank
    Yang, Jingsong
    Yee, Karen
    CANCER RESEARCH, 2023, 83 (08)
  • [5] Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
    Lee, Je-Hwan
    Faderl, Stefan
    Pagel, John M.
    Jung, Chul Won
    Yoon, Sung-Soo
    Pardanani, Animesh D.
    Becker, Pamela S.
    Lee, Howard
    Choi, Jeongeun
    Lee, Kyoungjune
    Kim, Minkyoung
    Cortes, Jorge E.
    BLOOD ADVANCES, 2020, 4 (09) : 2032 - 2043
  • [6] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    N Daver
    H Kantarjian
    F Ravandi
    E Estey
    X Wang
    G Garcia-Manero
    E Jabbour
    M Konopleva
    S O'Brien
    S Verstovsek
    T Kadia
    C Dinardo
    S Pierce
    X Huang
    N Pemmaraju
    M Diaz-Pines-Mateo
    J Cortes
    G Borthakur
    Leukemia, 2016, 30 : 268 - 273
  • [7] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Daver, N.
    Kantarjian, H.
    Ravandi, F.
    Estey, E.
    Wang, X.
    Garcia-Manero, G.
    Jabbour, E.
    Konopleva, M.
    O'Brien, S.
    Verstovsek, S.
    Kadia, T.
    Dinardo, C.
    Pierce, S.
    Huang, X.
    Pemmaraju, N.
    Diaz-Pines-Mateo, M.
    Cortes, J.
    Borthakur, G.
    LEUKEMIA, 2016, 30 (02) : 268 - 273
  • [8] A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    Chen, Yiming
    Kantarjian, Hagop
    Estrov, Zeev
    Faderl, Stefan
    Ravandi, Farhad
    Rey, Kristy
    Cortes, Jorge
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05): : 341 - 344
  • [9] Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Mims, Alice S.
    Solh, Melhem
    Saultz, Jennifer N.
    Borate, Uma
    Pemmaraju, Naveen
    Borthakur, Gautam
    Roboz, Gail J.
    Powell, Ben
    Matusow, Bernice
    Halladay, Jason
    Vali, Shireen
    Hope, Chelsea L.
    Kundu, Madan G.
    Hsu, Ching
    Watkins, Paul
    Zhang, Chao
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    DeZern, Amy E.
    BLOOD, 2021, 138
  • [10] Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Pemmaraju, Naveen
    Borate, Uma
    Solh, Melhem
    Borthakur, Gautam M.
    DeZern, Amy E.
    Zhang, Chao
    Powell, Ben
    Severson, Paul
    Inokuchi, Kerry
    Matusow, Bernice
    Halladay, Jason
    Hsu, Ching
    Watkins, Paul
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    Mims, Alice S.
    BLOOD, 2019, 134
12345